Anti-angiogenic therapy in the treatment of advanced renal cell cancer.
AffiliationCancer Research UK Department Medical Oncology, Christie Hospital, Manchester M20 4BX, UK. Ruth.Board@christie-tr.nwest.nhs.uk
MetadataShow full item record
AbstractMetastatic renal cell cancer is associated with a poor prognosis and is resistant to traditional chemotherapy agents. The majority of tumours are associated with inactivation of the von Hippel-Lindau gene and subsequent overexpression of proangiogenic factors, including vascular endothelial growth factor (VEGF). Drugs targeting these pathways have undergone clinical testing in renal cell cancer with encouraging results. This type of therapy is set to revolutionise the treatment of renal cell cancer and this review outlines recent evidence from clinical trials investigating the most promising of these agents.
CitationAnti-angiogenic therapy in the treatment of advanced renal cell cancer. 2007, 33 (1):1-8 Cancer Treat. Rev.
JournalCancer Treatment Reviews
- Bevacizumab as a treatment option in advanced renal cell carcinoma: an analysis and interpretation of clinical trial data.
- Authors: McDermott DF, George DJ
- Issue date: 2010 May
- Treatment targeted at vascular endothelial growth factor: a promising approach to managing metastatic kidney cancer.
- Authors: Schrader AJ, Varga Z, Pfoertner S, Goelden U, Buer J, Hofmann R
- Issue date: 2006 Mar
- Anti-angiogenic therapy in renal cell cancer.
- Authors: Srinivasan R, Armstrong AJ, Dahut W, George DJ
- Issue date: 2007 May
- The current role of angiogenesis inhibitors in the treatment of renal cell carcinoma.
- Authors: Choueiri TK, Bukowski RM, Rini BI
- Issue date: 2006 Oct
- Acceleration of clear cell renal cell carcinoma growth in mice following bevacizumab/Avastin treatment: the role of CXCL cytokines.
- Authors: Grepin R, Guyot M, Jacquin M, Durivault J, Chamorey E, Sudaka A, Serdjebi C, Lacarelle B, Scoazec JY, Negrier S, Simonnet H, Pages G
- Issue date: 2012 Mar 29